Chemotherapy-evoked painful peripheral neuropathy

Pain Medicine

Volumn 2, Issue 1, 2001, Pages 8-14

  Polomano, Rosemary C ^a   Bennett, Gary J ^b  

^a PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

^b DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

Allodynia; Chemotherapy neurotoxicity; Hyperalgesia; Neuropathy; Paclitaxel; Painful neuropathy; Vincristine

Indexed keywords

PACLITAXEL; VINCRISTINE;

ALLODYNIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CHEMOTHERAPY; CONTROLLED STUDY; DRUG INDUCED DISEASE; HISTOPATHOLOGY; HYPERALGESIA; MICROTUBULE; MOTOR SYSTEM; MOUSE; MYELINATED NERVE; NERVE DEGENERATION; NERVE INJURY; NEUROTOXICITY; NOCICEPTION; NOCICEPTIVE RECEPTOR; NONHUMAN; NONMYELINATED NERVE; PAIN; PERIPHERAL NEUROPATHY; RAT; SENSORIMOTOR FUNCTION; SENSORY NERVE CONDUCTION; SENSORY SYSTEM ELECTROPHYSIOLOGY;

EID: 0035022519     PISSN: 15262375     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1526-4637.2001.002001008.x     Document Type: Article

References (48)

1. Manfredi JJ, Horowitz SB. Taxol: an antimitotic agent with a new mechanism of action. Pharmacol Ther 1984;25:83-125.
2. Rowinsky EK, Donehower RC. Paclitaxel (taxol). N Engl J Med 1995;332:1004-14.
3. Wiernik PH, Schwartz EL, Einzig A, et al. Phase 1 trial of taxol given as a 24-hour infusion every 21 days: Responses observed in metastatic melanoma. J Clin Oncol 1987;5:1232-9.
4. Chaudhry V, Rowinsky EK, Sartorius SE, et al. Peripheral neuropathy from taxol and cisplatin combination chemotherapy: clinical and electrophysiological studies. Ann Neurol 1994;35:304-11.
5. Einzig AI, Wiernik PH, Sasloff J, et al. Phase II study and long-term follow-up of patients treated with taxol for advanced ovarian carcinoma. J Clin Oncol 1992;10:1748-53.
6. Kaplan JG, Einzig AI, Schaumburg HH. Taxol causes permanent large fiber peripheral nerve dysfunction: a lesson for preventative strategies. J Neurooncol 1993;16:105-7.
7. Parness J, Horowitz SB. Taxol binds to polymerized tubulin in vitro. J Cell 1991;9:479-87.
8. Fan W. Possible mechanisms of paclitaxel-induced apoptosis. Biochem Pharmacol 1999;57:1215-21.
9. Komiya Y, Tashiro T. Effects of taxol on slow and fast axonal transport. Cell Motil Cytoskeleton 1988; 11:151-6.
10. Pratt WB, Ruddon RW. The Anticancer Drugs. New York: Oxford University Press; 1974:221-33.
11. Legha SS. Vincristine neurotoxicity: pathophysiology and management. Med Toxicol 1986;1:421-7.
12. Hussain M, Wozniak AJ, Edelstein MB. Neurotoxicity of antineoplastic agents. Crit Rev Oncol Hematol 1993;14:61-75.
13. Forsyth PA, Balmaceda C, Peterson K, et al. Prospective study of paclitaxel-induced peripheral neuropathy with quantitative sensory testing. J Neurooncol 1997;35:47-53.
14. Holland JF, Scharlau C, Gailani S, et al. Vincristine treatment of advanced cancer: a cooperative study of 392 cases. Cancer Res 1973;33:1258-64.
15. Chabner BA, Myers CE. Clinical pharmacology of cancer chemotherapy. In: DeVita VT, Hellman S, Rosenberg SA, eds. Principles and Practice of Oncology. Vol. 1. Philadelphia: JB Lippincott Company; 1985:287-328.
16. Haim N, Epelbaum R, Ben-Shahar M, et al. Full dose vincristine (without 2-mg dose limit) in the treatment of lymphomas. Cancer 1994;73:2515-19.
17. Postma TJ, Heimans JJ, Muller MJ, et al. Pitfalls in grading severity of chemotherapy-induced peripheral neuropathy. Ann Oncol 1998;9:739-44.
18. Jerian SM, Sarosy GA, Link CJ, et al. Incapacitating autonomie neuropathy precipitated by taxol. Gynecol Oncol 1993;51:277-80.
19. van den Bent MJ, van Raaij-van den Aarssen VJ, Verweiji J, et al. Progression of paclitaxel-induced neuropathy following discontinuation of treatment. Muscle Nerve 1997;20:750-2.
20. Gruener G, Dyck PJ. Quantitative sensory testing: methodology, applications, and future directions. J Clin Neurophysiol 1994;11:568-83.
21. Yarnitsky D. Quantitative sensory testing. Muscle Nerve 1997;20:198-204.
22. Zaslansky R, Yarnitsky D. Clinical applications of quantitative sensory testing (QST). J Neurol Sci 1998;153:215-38.
23. 4-9 analogue against the toxic effects of ciplatin and taxol on sensory neurons and glial cells in vitro. J Neurosci Res 1994;39:178-85.
24. Boyle FM, Wheeler HR, Shenfield GM. Amelioration of experimental cisplatin and paclitaxel neuropathy with glutamate. J Neurooncol 1999;41:107-16.
25. Jackson DV, Wells HB, Atkins NJ, et al. Amelioration of vincristine neurotoxicity by glutamic acid. Am J Med 1988;84:1016-22.
26. Campana WM, Eskeland N, Calcutt NA, et al. Prosaptide prevents paclitaxel neurotoxicity. Neurotoxicology 1998;19:237-44.
27. Röyttä M, Raine CS. Taxol-induced neuropathy: further ultrastructural studies of nerve fibre changes in situ. J Neurocytol 1985;14:157-75.
28. Vuorinen V, Röyttä M., Raine CS. The long-term cellular response to taxol in peripheral nerve: Schwann cell and endoneurial cell changes. J Neurocytol 1989;18:785-94.
29. Nennesmo I, Reinholt FP. Effects of intraneural injection of taxol on retrograde axonal transport and morphology of corresponding nerve cell bodies. Virchows Arch B Cell Pathol Incl Mol Pathol 1988;55: 241-6.
30. Vuorinen V, Röyttä M, Raine CS. The acute effect of taxol upon regenerating axons after nerve crush. Acta Neuropathol (Berl) 1988;76:26-34.
31. Vuorinen V, Röyttä M. Taxol-induced neuropathy after nerve crush: long-term effects on regenerating axons. Acta Neuropathol (Berl) 1990;79:663-71.
32. Sahenk Z, Barohn RJ, New P, et al. Taxol neuropathy. Electrodiagnostic and sural nerve biopsy findings. Arch Neurol 1994;51:726-9.
33. Apfel SC, Lipton RB, Arezzo JC, et al. Nerve growth factor prevents toxic neuropathy in mice. Ann Neurol 1991;29:87-90.
34. Cavaletti G, Tredici G, Braga M, et al. Experimental peripheral neuropathy induced in adult rats by repeated intraperitoneal administration of taxol. Exp Neurol 1995;133:64-72.
35. Cavaletti G, Cavalletti E, Montaguti P, et al. Effect on the peripheral nervous system of the short-term intravenous administration of paclitaxel in the rat. Neurotoxicology 1997;18:137-45.
36. Cliffer KD, Siuciak JA, Carson SR, et al. Physiological characterization of taxol-induced large-fiber sensory neuropathy in the rat. Ann Neurol 1998;43: 46-55.
37. Polomano RC, Mannes AJ, Bennett GJ. Paclitaxel-induced painful peripheral neuropathy in rats. Soc Neurosci Abstr 1998;24:381.
38. Shelanski ML, Wisniewski H. Neurofibrillary degeneration induced by vincristine therapy. Arch Neurol 1969;20:199-206.
39. Schlaepfer WW. Vincristine-induced axonal alterations in rat peripheral nerve. J Neuropathol Exp Neurol 1971;30:488-505.
40. Todd GC, Griffing WJ, Gibson WR, et al. Animal models for the comparative assessment of neurotoxicity following repeated administration of vinca alkaloids. Cancer Treat Rep 1979;63:35-41.
41. Rebert CS, Pryor GT, Frick MS. Effects of vincristine, maytansine, and cis-platinum on behavioral and electrophysiological indices of neurotoxicity in the rat. J Appl Toxicol 1984;4:330-8.
42. Fiori MG, Schiavinato A, Lini E, et al. Peripheral neuropathy induced by intravenous administration of vincristine sulfate in the rabbit. An ultrastructural study. Toxicol Pathol 1995;23:248-55.
43. Aley KO, Reichling DB, Levine JD. Vincristine hyperalgesia in the rat: a model of painful vincristine neuropathy in humans. Neuroscience 1996;73: 259-65.
44. Tanner KD, Levine JD, Topp KS. Microtubule disorientation and axonal swelling in unmyelinated sensory axons during vincristine-induced painful neuropathy in rat. J Comp Neurol 1998;395:481-92.
45. Topp KS, Tanner KD, Levine JD. Damage to the cytoskeleton of large diameter sensory neurons and myelinated axons in vincristine-induced painful peripheral neuropathy in the rat. J Comp Neurol 2000; 424:563-76.
46. Ahlgren SC, White DM, Levine JD. Increased responsiveness of sensory neurons in the saphenous nerve of streptoxotocin-diabetic rat. J Neurophysiol 1992;68:2077-85.
47. Authier N, Coudore F, Eschalier A, et al. Pain related behaviour during vincristine-induced neuropathy in rats. NeuroReport 1999;10:965-8.
48. Sigurdardottir V, Bolund C, Sullivan M. Quality of life evaluation by the EORTC questionnaire technique in patients with generalized malignant melanoma on chemotherapy. Acta Oncol 1996;35: 149-58.